AAAAAA

   
Results: 1-6 |
Results: 6
THE NOVEL COMBINATION OF FAT CLEARANCE AND IMMUNOHISTOCHEMISTRY IMPROVES PREDICTION OF THE OUTCOME OF PATIENTS WITH COLORECTAL CARCINOMAS -A PRELIMINARY-STUDY
Authors: HABOUBI NY ABDALLA A AMINI S CLARK P DOUGAL M DUBE A SCHOFIELD P
Citation: Ny. Haboubi et al., THE NOVEL COMBINATION OF FAT CLEARANCE AND IMMUNOHISTOCHEMISTRY IMPROVES PREDICTION OF THE OUTCOME OF PATIENTS WITH COLORECTAL CARCINOMAS -A PRELIMINARY-STUDY, International journal of colorectal disease, 13(2), 1998, pp. 99-102
PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) HARVESTS IN MULTIPLE-MYELOMA - ANALYSIS OF FACTORS AFFECTING CONTENT AND EFFICACY
Authors: NAGESH K ROBERTSON J SHEEKEY D DOUGAL M CHANG J CHOPRA R MORGENSTERN GR TESTA NG SCARFFE JH
Citation: K. Nagesh et al., PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) HARVESTS IN MULTIPLE-MYELOMA - ANALYSIS OF FACTORS AFFECTING CONTENT AND EFFICACY, British Journal of Haematology, 101, 1998, pp. 282-282
PERFORMANCE STATUS AT PRESENTATION PREDICTS FOR SURVIVAL AFTER AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) TRANSPLANTATION IN MULTIPLE-MYELOMA
Authors: NAGESH K ROBERTSON J HOWE T DOUGAL M CHANG J MORGENSTERN GR CHOPRA R SCARFFE JH
Citation: K. Nagesh et al., PERFORMANCE STATUS AT PRESENTATION PREDICTS FOR SURVIVAL AFTER AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) TRANSPLANTATION IN MULTIPLE-MYELOMA, British Journal of Haematology, 101, 1998, pp. 283-283
RANDOMIZED PHASE-II STUDY OF BB-10010 (MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA) IN PATIENTS WITH ADVANCED BREAST-CANCER RECEIVING 5-FLUOROURACIL, ADRIAMYCIN, AND CYCLOPHOSPHAMIDE CHEMOTHERAPY
Authors: CLEMONS MJ MARSHALL E DURIG J WATANABE K HOWELL A MILES D EARL H KIERNAN J GRIFFITHS A TOWLSON K DETAKATS P TESTA NG DOUGAL M HUNTER MG WOOD LM CZAPLEWSKI LG MILLAR A DEXTER TM LORD BI
Citation: Mj. Clemons et al., RANDOMIZED PHASE-II STUDY OF BB-10010 (MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA) IN PATIENTS WITH ADVANCED BREAST-CANCER RECEIVING 5-FLUOROURACIL, ADRIAMYCIN, AND CYCLOPHOSPHAMIDE CHEMOTHERAPY, Blood, 92(5), 1998, pp. 1532-1540
CLINICAL AND IN-VITRO EFFECTS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN IN PATIENTS RECEIVING INTENSIVE CHEMOTHERAPY FOR SMALL-CELL LUNG-CANCER
Authors: DECAMPOS E RADFORD J STEWARD W MILROY R DOUGAL M SWINDELL R TESTA N THATCHER N
Citation: E. Decampos et al., CLINICAL AND IN-VITRO EFFECTS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN IN PATIENTS RECEIVING INTENSIVE CHEMOTHERAPY FOR SMALL-CELL LUNG-CANCER, Journal of clinical oncology, 13(7), 1995, pp. 1623-1631
A RANDOMIZED DOSE INTENSITY STUDY IN OVARIAN-CARCINOMA COMPARING CHEMOTHERAPY GIVEN AT 4 WEEK INTERVALS FOR 6 CYCLES WITH HALF DOSE CHEMOTHERAPY GIVEN FOR 12 CYCLES
Authors: MURPHY D CROWTHER D RENNINSON J PRENDIVILLE J RANSON M LIND M PATEL U DOUGAL M BUCKLEY CH TINDALL VR
Citation: D. Murphy et al., A RANDOMIZED DOSE INTENSITY STUDY IN OVARIAN-CARCINOMA COMPARING CHEMOTHERAPY GIVEN AT 4 WEEK INTERVALS FOR 6 CYCLES WITH HALF DOSE CHEMOTHERAPY GIVEN FOR 12 CYCLES, Annals of oncology, 4(5), 1993, pp. 377-383
Risultati: 1-6 |